ESC 365 - PCSK9-Inhibitions: for whom, when, and how effective.

Open Access

PCSK9-Inhibitions: for whom, when, and how effective.

Session: Secondary Prevention: unmet medical needs - Session I

Topic: Miscellaneous

Speaker: Professor C. Saely (Feldkirch, AT)

Event: EuroPrevent 2017

Congress Presentation

Add to my library

About the speaker

Professor Christoph Saely

VIVIT Institute, Feldkirch (Austria)

2 presentations

0 follower

3 more presentations in this session

Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population.

Speaker: Professor F. Visseren (Utrecht, NL)

Individual decision for length of dual antiplatelet therapy after ACS.

Speaker: Professor P. Clemmensen (Hamburg, DE)

New antidiabetic agents reduce cardiovascular events.

Speaker: Associate Professor J. Schmid (Gais, CH)

Access the full session

Secondary Prevention: unmet medical needs - Session I

Speakers: Professor C. Saely, Professor F. Visseren, Professor P. Clemmensen, Associate Professor J. Schmid

About the event

EuroPrevent 2017

6 April - 8 April 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources